Filing Details

The business address of the Reporting Persons is Box 984, 501 10 Boras, Sweden.

Frankenius Equity is a limited company organized in Sweden focusing on domestic and international ventures. Paul Frankenius is a board member and ultimate owner of Frankenius Equity.

During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Frankenius Equity was organized in Sweden and Paul Frankenius is a citizen of Sweden.

Item 4 of the Statement is hereby amended and supplemented as follows: On April 30, 2025, in connection with a private financing of the Issuer's equity securities (the "Private Placement") and as a condition of the investors entering into the purchase agreement for the Private Placement, the Issuer entered into a tender and support agreement (the "Support Agreement") with certain holders (the "Supporting Holders"), including Frankenius Equity, of shares of the Issuer's outstanding Series A preferred stock (the "Preferred Stock"). Pursuant to the Support Agreement, Frankenius Equity has committed, subject to the terms and conditions thereof, to exchange its Preferred Stock for shares of common stock in the Exchange Offer (as defined herein) to be undertaken by the Issuer. Additionally, pursuant to the Support Agreement, Frankenius Equity has agreed to vote its shares of Preferred Stock in favor of an amendment to the Certificate of Designations, Preferences and Rights for the Preferred Stock to alter certain of the terms of the Preferred Stock as further described in Item 6 of this Amendment No. 2. The information included in Item 6 of this Amendment No. 2 is incorporated by reference herein.

The information set forth in rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D/A is incorporated by reference. The percentage set forth in each row 13 is based upon the sum of (i) 32,335,246 shares of common stock outstanding as of April 17, 2025, as reported in the Issuer's definitive proxy statement, filed with the SEC on April 30, 2025; (ii) 435,853 shares of common stock issuable upon conversion of Series A preferred stock; and (iii) 65,915 shares of common stock issuable upon conversion of dividends within 60 days of this filing.

The information set forth in rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A and Item 2 above is incorporated by reference.

Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuer's common stock during the last 60 days.

No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of common stock subject to this Schedule 13D/A.

Not applicable.

Item 6 of the Statement is hereby amended and supplemented as follows: Tender and Support Agreement Pursuant to the terms of the Support Agreement, the Issuer agreed to (i) initiate an exchange offer (the "Exchange Offer") pursuant to a registration statement on Form S-4 to be filed with the SEC to offer all holders of the Preferred Stock the opportunity to exchange their Preferred Stock for common stock, with each share of Preferred Stock offered to be exchanged into a number of shares of common stock equal to the quotient of (A) the sum of (1) $10.00, which is the liquidation preference per share of the Preferred Stock (the "Liquidation Preference"), and (2) all accrued and unpaid dividends per share on the Preferred Stock calculated as if such share remained outstanding on August 10, 2027 and dividends were being paid then, divided by (B) $4.00, and (ii) concurrent with the Exchange Offer, set a special meeting (the "Special Meeting") to submit to the vote of the holders of Preferred Stock an amendment to the Certificate of Designations, Preferences and Rights for the Preferred Stock (the "Amendment") to: (A) add the right of the Issuer to call, at any time, all or any portion of the then-outstanding shares of Preferred Stock for conversion into shares of common stock equal to the quotient of (x) the sum of (1) the Liquidation Preference and (2) all accrued and unpaid dividends per share on the Preferred Stock as of the conversion date, divided by (y) $5.277, which is the current conversion price per share for the Preferred Stock, and (B) eliminate the conversion price reset provision in the Certificate of Designations, Preferences and Rights for the Preferred Stock whereby the conversion price of the Preferred Stock is subject to possible downward adjustment in July 2027. The per share amounts set forth above in this paragraph are subject to adjustment for the same adjustment events as apply to the conversion price for the Preferred Stock and are set forth in the Certificate of Designations, Preferences and Rights for the Preferred Stock. The affirmative vote of the holders representing at least a majority of the outstanding shares of Preferred Stock is required to approve the Amendment. The Supporting Holders, including Frankenius Equity, collectively hold approximately 55% of the shares of Preferred Stock outstanding and have agreed to tender and exchange all of their shares of Preferred Stock in the Exchange Offer and to vote all of their shares of Preferred Stock to approve or consent to the Amendment and any other proposal required for the adoption of the Amendment or the consummation of the Exchange Offer. The Issuer has agreed to take all steps reasonably necessary or desirable to commence the Exchange Offer and hold the Special Meeting as soon as practicable. The Support Agreement shall terminate upon the earlier of (i) the date the Issuer 's board of directors or committee thereof determines to no longer pursue the Exchange Offer, and (ii) September 30, 2025. The foregoing description of the Support Agreement, including the proposed Amendment, which is attached as an exhibit to the Support Agreement, does not purport to be complete and is qualified in its entirety by reference to the Support Agreement, a copy of which is filed as Exhibit 99.1 hereto and incorporated by reference herein.

Exhibit 99.1 Tender and Support Agreement, dated April 30, 2025, by and among TriSalus Life Sciences, Inc. and the persons party thereto (incorporated by reference to Exhibit 10.3 to the Issuer's Current Report on Form 8-K, filed with the SEC on April 30, 2025).